Laden…
(4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
Oxycodone is a semisynthetic opioid primarily used as a strong analgesic. It acts primarily as an agonist at the μ-opioid receptor, thereby influencing pain processing in the central nervous system. Due to its high potential for addiction and risks for respiratory depression, careful handling is required. The substance is medically used for the treatment of moderate to severe pain.
Class
Opioide
Pharmacological context
Mechanism
Oxycodone primarily acts as an agonist at the μ-opioid receptor,...
Short read on known pharmacology
Interactions
No curated pairs visible
Curated visible combinations
Risk theme
Interpret risks carefully
Condensed from structured notes
Receptor Targets
Mechanism of Action
Designations
IUPAC: (4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Substance Fingerprint
Pharmacological profile based on receptor binding, mechanism of action, and substance class. Limited data — interpret profile with caution.
Synapedia Evidence
Frequently checked combinations
Oxycodone primarily acts as an agonist at the μ-opioid receptor, leading to inhibition of pain transmission in the central nervous system. This results in analgesic effects as well as potential sedation.
Known Effects
Individual effects may vary significantly. These are pharmacologically documented effects.
Reported range 10–20 mg
Total duration 4–6 hours
Oral
| Tier | Dosage |
|---|---|
| Light | 5–10 mg |
| Reported | 10–20 mg |
| Strong | 20–40 mg |
Nasal
| Tier | Dosage |
|---|---|
| Light | 2–5 mg |
| Reported | 5–10 mg |
| Strong | 10–20 mg |
Sublingual
| Tier | Dosage |
|---|---|
| Light | 2–5 mg |
| Reported | 5–10 mg |
| Strong | 10–20 mg |
IV
| Tier | Dosage |
|---|---|
| Light | 1–2 mg |
| Reported | 2–5 mg |
| Strong | 5–10 mg |
Onset
30–60 minutes
Peak
1–2 hours
Total duration
4–6 hours
After effects
2–4 hours
Avoid uncertain dosage claims and do not infer numbers when data is unclear.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Evidence
strong
Safer Use
Depressant-risk context
This substance belongs to a context where combinations with opioids, benzodiazepines, alcohol, GHB/GBL, or other sedating substances can increase sedation, blackout, aspiration, and breathing-risk patterns. Risk Check can review warning patterns; it is not medical advice and it cannot clear a combination as safe.
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.